Geisinger Medical Laboratories Test Catalog
RET SEQUENCING AND DELETION/DUPLICATION |
||
ORDERING INFORMATION: |
Geisinger Epic Procedure Code: LAB1341 Geisinger Epic ID: 53289 | |
SPECIMEN COLLECTION |
||
Specimen type: |
Whole blood | |
Preferred collection container: |
||
Specimen required: |
5 mL whole blood; minimum 2 mL. | |
Special notes: |
Send report of results for family member with known mutation. | |
SPECIMEN PROCESSING |
||
Transport temperature: |
Specimen stability is crucial. Store and ship room temperature immediately. Do not freeze. | |
Specimen stability: |
Room temperature: 14 days. Refrigerated: 14 days. Frozen: Unacceptable. | |
Rejection criteria: |
Gross hemolysis • Clotted | |
TEST DETAILS |
||
Additional information: |
This test was developed and its analytical performance characteristics have been determined by Quest Diagnostics. It has not been cleared or approved by the FDA. This assay has been validated pursuant to the CLIA regulations and is used for clinical purposes. | |
CPT code(s): |
81406, 81479 | |
Note: The billing party has sole responsibility for CPT coding. Any questions regarding coding should be directed to the payer being billed. The CPT codes provided by GML are based on AMA guidelines and are for informational purposes only. | ||
Test includes: |
If "Result" is positive, cascading reflex to Path Variant and VUS will be performed as needed. | |
Methodology: |
Next Generation Sequencing with Microarray Confirmation Long-Range Polymerase Chain Reaction DNA Bait Capture |
|
Synonyms: |
Quest test code 93796, RET Sequenci
|
|
Clinical significance: |
Germline mutations within the RET proto-oncogene cause Multiple endocrine neoplasia type 2 (MEN 2), with a high lifetime risk of medullary thyroid cancer and pheochromocytoma. This test detects pathogenic variants in the RET proto-oncogene. |